Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death

Molecular Nutrition and Food Research

Volumn 57, Issue 7, 2013, Pages 1170-1181

  Aires, Virginie ^a,b   Limagne, Emeric ^a,c   Cotte, Alexia K ^a,b   Latruffe, Norbert ^a,c   Ghiringhelli, François ^a,b   Delmas, Dominique ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b boulevard Jeanne d'Arc   (France)

^c UFR Sciences Vie Terre et Environnement   (France)

Author keywords

Cell cycle; Colon cancer; Metabolites; Polyphenols; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCURONIDE; POLYPHENOL; RESVERATROL; RESVERATROL 4' O GLUCURONIDE; RESVERATROL-4'-O-GLUCURONIDE; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLON TUMOR; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; METABOLITES; TUMOR CELL LINE;

CELL CYCLE; COLON CANCER; METABOLITES; POLYPHENOLS; RESVERATROL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SYNERGISM; GLUCURONIDES; HUMANS; STILBENES;

RICE STRIPE VIRUS;

EID: 84879799217     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200766     Document Type: Article

References (49)

1. Renaud, S. C., Gueguen, R., Schenker, J., d'Houtaud, A., Alcohol and mortality in middle-aged men from eastern France. Epidemiology 1998, 9, 184-188.
2. Delmas, D., Jannin, B., Latruffe, N., Resveratrol: preventing properties against vascular alterations and ageing. Mol. Nutr. Food Res. 2005, 49, 377-395.
3. Delmas, D., Lancon, A., Colin, D., Jannin, B. et al., Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr. Drug Targets. 2006, 7, 423-442.
4. Kroon, P. A., Iyer, A., Chunduri, P., Chan, V. et al., The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr. Med. Chem. 2010, 17, 2442-2455.
5. Shih, A., Zhang, S., Cao, H. J., Boswell, S. et al., Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol. Cancer Ther. 2004, 3, 1355-1364.
6. Lin, H. Y., Shih, A., Davis, F. B., Tang, H. Y. et al., Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J. Urol. 2002, 168, 748-755.
7. Colin, D., Gimazane, A., Lizard, G., Izard, J. C. et al., Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int. J. Cancer 2009, 124, 2780-2788.
8. Marel, A. K., Lizard, G., Izard, J. C., Latruffe, N. et al., Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells. Mol. Nutr. Food Res. 2008, 52, 538-548.
9. Delmas, D., Rebe, C., Lacour, S., Filomenko, R. et al., Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem. 2003, 278, 41482-41490.
10. Harikumar, K. B., Kunnumakkara, A. B., Sethi, G., Diagaradjane, P. et al., Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer 2010, 127, 257-268.
11. Fulda, S., Debatin, K. M., Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004, 23, 6702-6711.
12. Delmas, D., Rebe, C., Micheau, O., Athias, A. et al., Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004, 23, 8979-8986.
13. Baur, J. A., Sinclair, D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506.
14. Gescher, A. J., Steward, W. P., Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 953-957.
15. Delmas, D., Lin, H. Y., Role of membrane dynamics processes and exogenous molecules in cellular resveratrol uptake: consequences in bioavailability and activities. Mol. Nutr. Food Res. 2011, 55, 1142-1153.
16. Lancon, A., Hanet, N., Jannin, B., Delmas, D. et al., Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos. 2007, 35, 699-703.
17. Wenzel, E., Soldo, T., Erbersdobler, H., Somoza, V., Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 2005, 49, 482-494.
18. Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49, 472-481.
19. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M. et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246-1252.
20. Patel, K. R., Brown, V. A., Jones, D. J., Britton, R. G. et al., Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70, 7392-7399.
21. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
22. Almeida, L., Vaz-da-Silva, M., Falcao, A., Soares, E. et al., Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009, 53, S7-15.
23. Nunes, T., Almeida, L., Rocha, J. F., Falcao, A. et al., Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J. Clin. Pharmacol. 2009, 49, 1477-1482.
24. Patel, K. R., Scott, E., Brown, V. A., Gescher, A. J. et al., Clinical trials of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 161-169.
25. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A. et al., What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One, 6, e19881.
26. Delmas, D., Jannin, B., Malki, M. C., Latruffe, N., Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol. Rep. 2000, 7, 847-852.
27. Delmas, D., Passilly-Degrace, P., Jannin, B., Malki, M. C., Latruffe, N., Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells. Int. J. Mol. Med. 2002, 10, 193-199.
28. Camont, L., Cottart, C. H., Rhayem, Y., Nivet-Antoine, V. et al., Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal. Chim. Acta 2009, 634, 121-128.
29. Colin, D., Limagne, E., Jeanningros, S., Jacquel, A. et al., Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. Cancer Prev. Res. (Phila) 2011, 4, 1095-1106.
30. Pagano, M., Pepperkok, R., Lukas, J., Baldin, V. et al., Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J. Cell Biol. 1993, 121, 101-111.
31. Heiss, E. H., Schilder, Y. D., Dirsch, V. M., Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J. Biol. Chem. 2007, 282, 26759-26766.
32. Young, L. F., Martin, K. R., Time-dependent resveratrol-mediated mRNA and protein expression associated with cell cycle in WR-21 cells containing mutated human c-Ha-Ras. Mol. Nutr. Food Res. 2006, 50, 70-77.
33. Tyagi, A., Singh, R. P., Agarwal, C., Siriwardana, S. et al., Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 2005, 26, 1978-1987.
34. Gatz, S. A., Keimling, M., Baumann, C., Dork, T. et al., Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner. Carcinogenesis 2008, 29, 519-527.
35. Rougier, P., Mitry, E., Colorectal cancer chemotherapy: irinotecan. Semin. Oncol. 2000, 27, 138-143.
36. Gongora, C., Vezzio-Vie, N., Tuduri, S., Denis, V. et al., New Topoisomerase I mutations are associated with resistance to camptothecin. Mol. Cancer 2011, 10, 64.
37. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C., Beaudeux, J. L., Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7-16.
38. Kuwajerwala, N., Cifuentes, E., Gautam, S., Menon, M. et al., Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 2002, 62, 2488-2492.
39. Bernhard, D., Tinhofer, I., Tonko, M., Hubl, H. et al., Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ. 2000, 7, 834-842.
40. Dorrie, J., Gerauer, H., Wachter, Y., Zunino, S. J., Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001, 61, 4731-4739.
41. Reis-Sobreiro, M., Gajate, C., Mollinedo, F., Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene 2009, 28, 3221-3234.
42. She, Q. B., Bode, A. M., Ma, W. Y., Chen, N. Y. et al., Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001, 61, 1604-1610.
43. Crozier, A., Jaganath, I. B., Clifford, M. N., Dietary phenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep. 2009, 26, 1001-1043.
44. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A. et al., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70, 9003-9011.
45. Hoshino, J., Park, E. J., Kondratyuk, T. P., Marler, L. et al., Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 2011, 53, 5033-5043.
46. Calamini, B., Ratia, K., Malkowski, M. G., Cuendet, M. et al., Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 2010, 429, 273-282.
47. Cardoso, M. C., Leonhardt, H., Nadal-Ginard, B., Reversal of terminal differentiation and control of DNA replication: cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 1993, 74, 979-992.
48. Yun, H. J., Hyun, S. K., Park, J. H., Kim, B. W. et al., Widdrol activates DNA damage checkpoint through the signaling Chk2-p53-Cdc25A-p21-MCM4 pathway in HT29 cells. Mol. Cell. Biochem. 2012, 363, 281-289.
49. Bartkova, J., Horejsi, Z., Koed, K., Kramer, A. et al., DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434, 864-870.